Showing results (71-80 of 216) with videos related to
Sort By:
Pageof 22
Clinical Lung Cancer|June 7, 2017
Comparison of Radiotherapy and Chemoradiotherapy for Locoregional Recurrence of Non-small-cell Lung Cancer Developing After SurgeryShinji Nakamichi, Hidehito Horinouchi, Tetsuhiko Asao, et al.Clinical Lung Cancer|May 10, 2026
A Multi-Institutional Randomized Phase III Trial of Neoadjuvant Chemoimmunotherapy Followed By Surgery Versus Upfront Surgery in Patients With Resectable Clinical Stage II-III Non-Small Cell Lung Cancer: JCOG2317 (NATCH-ICI)Noriko Mitome, Akira Hamada, Masashi Wakabayashi, et al.Cancer Immunology, Immunotherapy : CII|November 21, 2019
Association of immune-related pneumonitis with the presence of preexisting interstitial lung disease in patients with non-small lung cancer receiving anti-programmed cell death 1 antibodyRyota Shibaki, Shuji Murakami, Yuji Matsumoto, et al.Cancer Immunology, Immunotherapy : CII|March 11, 2020
Predictive value of serum VEGF levels for elderly patients or for patients with poor performance status receiving anti-PD-1 antibody therapy for advanced non-small-cell lung cancerRyota Shibaki, Shuji Murakami, Yuki Shinno, et al.Medical Oncology (Northwood, London, England)|April 29, 2019
Tumor expression and usefulness as a biomarker of programmed death ligand 1 in advanced non-small cell lung cancer patients with preexisting interstitial lung diseaseRyota Shibaki, Shuji Murakami, Yuji Matsumoto, et al.Cancer Chemotherapy and Pharmacology|August 4, 2018
An open-label feasibility study of nintedanib combined with docetaxel in Japanese patients with locally advanced or metastatic lung adenocarcinoma after failure of first-line chemotherapyNoboru Yamamoto, Hirotsugu Kenmotsu, Koichi Goto, et al.Journal of Cancer Research and Clinical Oncology|July 25, 2020
Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expressionKen Masuda, Hidehito Horinouchi, Midori Tanaka, et al.Cancer Immunology, Immunotherapy : CII|June 28, 2021
Prognostic significance of cachexia in advanced non-small cell lung cancer patients treated with pembrolizumabHitomi Jo, Tatsuya Yoshida, Hidehito Horinouchi, et al.Journal of Cancer Research and Clinical Oncology|April 26, 2024
Efficacy and safety of chemoimmunotherapy in advanced non-small cell lung cancer patients with antibiotics-induced dysbiosis: a propensity-matched real-world analysisKentaro Tamura, Yusuke Okuma, Shogo Nomura, et al.Japanese Journal of Clinical Oncology|February 11, 2026
Immune checkpoint inhibitors in nuclear protein in testis carcinoma treatment: evidence of limited clinical benefits from a case seriesTomoaki Nakamura, Tatsuya Yoshida, Akihiko Yoshida, et al.Pageof 22